The therapy is a bispecific antibody about to enter phase 2 studies targeting atopic dermatitis, a common inflammatory skin disease. Pending regulatory approval, J&J expects to acquire the drug candidate from Switzerland-based Numab Therapeutics in the second half of 2024.
Beyond the robot: What separates successful outpatient joint programs
Presenters: James Germano, MD, Joint Reconstruction SpecialistTim Tzimas, Innovative Sterilization Technologies
Comments are closed.